BsAbs work by utilizing their two binding sites to engage both a cancer cell and an immune cell, such as a T-cell. One arm of the antibody binds to a specific antigen on the surface of cancer cells, while the other arm binds to an activating receptor on immune cells, such as CD3 on T-cells. This brings the immune cells in close proximity to the cancer cells, facilitating targeted cytotoxic activity and enhancing the immune system's ability to eliminate the tumor.
